Horizon Pharma nets $81.1mm through FOPO

Horizon Pharma Inc. (neurology, muscloskeletal, and inflammation therapeutics) has netted $81.1mm through the follow-on public offering of 24.6mm common shares (including the overallotment) at $3.50. The investors also received five-year warrants to buy another 10.7mm shares at $4.57. The company will use the money for commercialization activities for its Duexis (for rheumatoid arthritis, osteoarthritis, and to decrease the risk of developing upper gastrointestinal ulcers) and Rayos (for rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma, and chronic obstructive pulmonary disease).